F-star Presents New Data on OX40/CD137 Tetravalent Bispecific Antibody at the SITC 2019 Annual Meeting
8.11.2019 15:00:00 EET | Business Wire | Press release
F-star Therapeutics (“F-star”), a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies, today announces that new preclinical data on FS120, a mAb² product candidate targeting OX40 and CD137, will be presented at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting in National Harbor, Maryland, United States, being held from 06 - 10 November 2019.
FS120 is a potentially best-in-class dual agonist that has the potential to overcome cancer resistance by simultaneously engaging OX40 (CD134, TNFRSF4) and CD137 (4-1BB), two receptors found on the surface of tumor-infiltrating lymphocytes. Targeting this class of receptors using bispecific tetravalent binding mobilizes multiple arms of the immune system, which research shows is essential for eliminating tumors. F-star’s preclinical data demonstrated that FS120’s crosslink-dependent approach has the potential to provide therapeutic benefit, for example in combination with checkpoint antagonists, and reverse T cell exhaustion in immunosuppressive tumor environments.
Neil Brewis, CSO of F-star said “Recent clinical trials involving agonist molecules have reported that a meaningful anti-cancer response is often associated with liver toxicity, in line with preclinical observations. F-star’s OX40/CD137 mAb² antibody is showing preclinical evidence that an effective tumor-killing response can be decoupled from liver inflammation. We look forward to progressing FS120 into the clinic as we aim to potentially improve treatment outcomes for patients with difficult-to-treat cancers.”
Some CD137 agonist antibodies have been shown to induce adverse effects either in clinical or in preclinical studies as they constitutively activate T cells and thus release cytotoxic immunity outside of the tumor. In contrast, FS120 is designed to mitigate off-target toxicity through conditional, crosslink-dependent activation upon binding to both OX40 and CD137, which are predominantly present on T cells in the tumor microenvironment.
F-star expects to submit an IND application for FS120 during the fourth quarter of 2019.
Details of the poster are below:
Crosslink-independent CD137 agonism is associated with liver inflammation
Abstract poster number: P775
Poster hall location: Prince George AB
Poster hall hours: 07:00 to 20:00 on Friday 08 November 2019
Poster presentation hours: 12:30 to 14:00 and 18:30 to 20:00 on Friday 08 November 2019
- ENDS -
About F-star
F-star is a clinical-stage immuno-oncology company singularly focused on transforming the lives of patients with cancer through the development of its innovative tetravalent mAb2 bispecific antibodies. With four distinct binding sites in a natural human antibody format, F-star believes its proprietary approach will overcome many of the challenges facing current immuno-oncology therapies. F-star’s vision is to transform the treatment of cancer through the development of differentiated and well-tolerated mAb2 bispecific antibodies, which are designed to simultaneously address multiple immune evasion pathways that limit the effect of current immuno-oncology therapies.
mAb2™ is a trademark of F-star.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191108005210/en/
Contact information
For investor enquiries
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@f-star.com
Consilium Strategic Communications
Chris Gardner, Sue Stuart, David Daley
Tel: +44 (0)20 3709 5700
E-mail: F-star@consilium-comms.com
For media enquiries
Pierre Peotta
Communications Manager
+44 (0)1223 948 094
+44 (0)7392 080 279
pierre.peotta@f-star.com
US
Catherine London, US President
Tel: +1 917-763-2709
E-mail: F-star@consilium-comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 13:45:00 EEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time building and updating planograms and more time acting on opportunities. With greater automation, retailers can improve productivi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom